Pharma Mar SA ( (PHMMF) ) has released its Q4 earnings. Here is a breakdown of the information Pharma Mar SA presented to its investors.
Pharma Mar SA is a biotechnology company specializing in the development and commercialization of marine-derived drugs for oncology and RNA interference-based therapies. The company is known for its innovative approach in the pharmaceutical industry, particularly in cancer treatment.
Pharma Mar SA reported a robust financial performance for the year ending December 2024, with group revenue increasing by 11% to €174.9 million. The company also saw a significant rise in royalties and licensing agreements, contributing to a substantial improvement in EBITDA and net profit compared to the previous year.
Key financial highlights include an 18% increase in royalties from sales of Yondelis and Zepzelca, and a 38% rise in revenues under licensing agreements. The company’s R&D expenditure grew by 4%, reflecting ongoing clinical trials and development activities. Notably, the oncology segment saw a decline in net revenue, but this was offset by increased royalties and licensing income.
Strategically, Pharma Mar and its partner Jazz Pharmaceuticals announced positive clinical trial results for lurbinectedin, with plans to submit applications for regulatory approval in the US and EU. The completion of the first phase of an oligonucleotide production plant also marks a significant milestone in the company’s RNA interference segment.
Looking ahead, Pharma Mar’s management remains optimistic about the company’s growth prospects, driven by ongoing clinical developments and strategic partnerships. The company is well-positioned to continue its investment in R&D and expand its market presence in the oncology and RNA interference sectors.